Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.

@article{Saggar2012BriefRE,
  title={Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.},
  author={Rajeev Saggar and Dinesh Khanna and Shelley Shapiro and Daniel e. Furst and Paul M Maranian and Philip Clements and Fereidoun Abtin and Shiv B. Dua and John A Belperio and Rajan Saggar},
  journal={Arthritis and rheumatism},
  year={2012},
  volume={64 12},
  pages={4072-7}
}
OBJECTIVE Exercise-induced pulmonary hypertension (ePH) may represent an early, clinically relevant phase in the spectrum of pulmonary vascular disease. The purpose of this pilot study was to describe the changes in hemodynamics and exercise capacity in patients with systemic sclerosis (SSc) spectrum-associated ePH treated with open-label daily ambrisentan… CONTINUE READING